Skip to main content
Clinical Trials/CTRI/2024/08/072874
CTRI/2024/08/072874Not yet recruitingPhase 2

A clinical study on kampavata with special reference to Parkinsons disease and its management with indigenous drug

Dr Neha Tiwari1 site in 1 country40 target enrollmentStarted: August 28, 2024Last updated:

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
To prevent signs and symptoms of Parkinsons disease in patients

Study Overview

Brief Summary

This study a single blind randomized controlled trial of 3 months duration to compare efficacy of indigenous drug and levodopa in patients suffering from Kampavata with special reference to Parkinsons disease. The primary outcome is to prevent Parkinsons disease in patients and secondary outcome is to reduce tremor rigidity bradykinesia and postural disturbance in patients.

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 80.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patient having the clinical sign and symptoms of Parkinsons disease.

Exclusion Criteria

  • Patient aged below 18years and above 80years Patient having heart diseases Malignancies Hypothyroidism Uncontrolled Hypertension and Diabetes Mellitus Cerebrovascular accidents Alzheimers disease.

Outcomes

Primary Outcomes

To prevent signs and symptoms of Parkinsons disease in patients

Time Frame: 3months

Secondary Outcomes

  • To reduce tremor rigidity bradykinesia postural disturbance in patients(3months)

Investigators

Sponsor
Dr Neha Tiwari
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Neha Tiwari

Gopabandhu Ayurveda Mahavidyalaya Puri

Study Sites (1)

Loading locations...

Similar Trials